← Russell 3000 cross-section

CI Cigna Group

Trailing twelve months to 2026-06-30 · as filed 2026-07-30, not restated
Financials

Scale

Market cap
$73.9bn
Revenue TTM
$282.4bn
Net income TTM
$6.2bn
Free cash flow
Composite score
58.0
Sector rank
#173

Valuation

P / E
11.9
EV / EBITDA
5.5
EV / sales
0.2
FCF yield
Earnings yield vs 10-yr
3.70pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
2.2%
EBITDA margin
4.5%
ROE
14.6%
ROIC
26.1%
Revenue growth
7.8%

Insider activity, last 90 days

Net open-market
$-6.39m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Shareholders' net income increased 8% and 16% for the three and six months ended, respectively, primarily reflecting higher adjusted income from operations in Cigna Healthcare. Pharmacy revenues increased 7% and 9% for the three and six months ended, respectively, primarily reflecting changes in claims composition (defined in the "Segment Reporting" section) within our Pharmacy Benefit Services operating segment. Premiums increased 8% for the three months ended, primarily driven by higher premium rates within Cigna Healthcare, and decreased 10% for the six months ended, primarily driven by the impact of the HCSC transaction (defined in the "Segment Reporting" section) (-17%), offset primaril …Cigna Group, 10-Q, period ended 2026-06-30, filed 2026-07-30

Read the full passage →